CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $19.57M, lower than 95% of all stocks globally
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
14.49MGBP19.57M · vs all stocks (USD)
Revenue (TTM)
1.15MGBP1.56M · vs all stocks (USD)
Beta
0.4270xvs all stocks
52-Week Change
-42.05%vs all stocks
Market Capitalization
14.49MGBP19.57M · vs all stocks (USD)
Enterprise Value
12.93MGBP17.46M · vs all stocks (USD)
Forward P/E
-31.88xvs Diagnostics & Research peers
Price to Sales (TTM)
12.58xvs Diagnostics & Research peers
Price to Book (MRQ)
3.19xvs Diagnostics & Research peers
Enterprise to Revenue
11.22xvs Diagnostics & Research peers
Enterprise to EBITDA
-2.12xvs Diagnostics & Research peers
Operating Margin
-444.05%vs Diagnostics & Research peers
Return on Assets (TTM)
-37.24%vs Diagnostics & Research peers
Return on Equity (TTM)
-163.78%vs Diagnostics & Research peers
Revenue (TTM)
1.15MGBP1.56M · vs all stocks (USD)
Revenue per Share (TTM)
0.0020GBPUpdated Jul 28, 2026Quarterly Revenue Growth
-25.00%vs Diagnostics & Research peers
Gross Profit (TTM)
-333.00KGBP-449.73K · vs all stocks (USD)
EBITDA (TTM)
-6.11MGBP-8.24M · vs all stocks (USD)
Net Income (TTM)
-12.94MGBP-17.48M · vs all stocks (USD)
Operating Cash Flow (TTM)
-8.66MGBP-11.70M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.04MGBP-2.75M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Diagnostics & Research peers
Revenue
2.86MGBPFY2024 · Dec 31, 2024Cost of Goods Sold
1.08MGBPFY2024 · Dec 31, 2024Gross Profit
1.78MGBPFY2024 · Dec 31, 2024Operating Income
-15.47MGBP-20.90M · vs all stocks (USD)
Pre-tax Income
-15.03MGBPFY2024 · Dec 31, 2024Income Tax Expense
-804.00KGBPFY2024 · Dec 31, 2024Net Income
-14.22MGBPFY2024 · Dec 31, 2024EBIT
-14.72MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-13.01MGBPFY2024 · Dec 31, 2024Research & Development
1.77MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
455.00KGBPFY2024 · Dec 31, 2024Other Operating Expenses
4.19MGBPFY2024 · Dec 31, 2024Non-operating Interest Income
396.00KGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
307.00KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0482GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0482GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
294.93MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
294.93MSharesFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-13.79MGBPFY2024 · Dec 31, 2024Free Cash Flow
-14.21MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
10.43MGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-15.03MGBPFY2024 · Dec 31, 2024Stock-based Compensation
1.45MGBPFY2024 · Dec 31, 2024Other Non-cash Items
-67.00KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-304.00KGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
153.00KGBPFY2024 · Dec 31, 2024Capital Expenditures
-411.00KGBPFY2024 · Dec 31, 2024Net Intangibles (CF)
-33.00KGBPFY2024 · Dec 31, 2024Net Investing Cash Flow
-411.00KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
8.63MGBPFY2024 · Dec 31, 2024Shares Outstanding
1.14BSharesUpdated Jul 28, 2026Float Shares
491.63MSharesUpdated Jul 28, 2026% Held by Insiders
5.69%vs all stocks
% Held by Institutions
33.30%vs all stocks
Total Cash (MRQ)
2.88MGBP3.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0030GBPUpdated Jul 28, 2026Total Debt (MRQ)
1.31MGBP1.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3190xvs Diagnostics & Research peers
Current Ratio (MRQ)
2.54xvs Diagnostics & Research peers
Book Value per Share (MRQ)
0.0040GBPUpdated Jul 28, 2026Total Assets
25.46MGBP34.38M · vs all stocks (USD)
Total Current Assets
16.41MGBPFY2024 · Dec 31, 2024Total Liabilities
7.02MGBPFY2024 · Dec 31, 2024Total Non-current Assets
9.05MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
3.76MGBPFY2024 · Dec 31, 2024Total Current Liabilities
3.26MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
10.43MGBPFY2024 · Dec 31, 2024Accounts Receivable
774.00KGBPFY2024 · Dec 31, 2024Inventory
1.58MGBPFY2024 · Dec 31, 2024Accounts Payable
695.00KGBPFY2024 · Dec 31, 2024Short-term Debt
862.00KGBPFY2024 · Dec 31, 2024Long-term Debt
3.35MGBPFY2024 · Dec 31, 2024Common Stock (Book)
32.26MGBPFY2024 · Dec 31, 2024Retained Earnings
-133.15MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
18.44MGBP24.91M · vs all stocks (USD)
52-Week Low
0.8500GBXUpdated Jul 28, 202652-Week High
2.92GBXUpdated Jul 28, 202652-Week Change
-42.05%vs all stocks
Beta
0.4270xvs all stocks
50-Day MA
1.56GBXUpdated Jul 28, 2026200-Day MA
1.29GBXUpdated Jul 28, 2026Avg 10-Day Volume
1.31MSharesUpdated Jul 28, 2026Avg 30-Day Volume
1.68MSharesUpdated Jul 28, 2026Diluted EPS (TTM)
-0.0300GBPUpdated Jul 28, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $19.57M, lower than 95% of all stocks globallySignificant
Market cap (USD): 19,568,009.979Global P5: 269,387,740.27
Revenue is $1.56M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,555,810.56Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Kropz PLC
Tier 1ProductionThroughput-Bound ConversionFlowRule
Eco Buildings Group plc
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Genedrive Plc
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Northern Bear Plc
Tier 1ProductionThroughput-Bound ConversionFlowRule
Light Science Technologies Holdings plc
Tier 1ProductionThroughput-Bound ConversionFlowRule
Haydale Graphene Industries plc
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Harvard Bioscience, Inc.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Directa Plus Plc
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Eenergy Group Plc
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Clean Power Hydrogen plc
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Twist Bioscience Corporation
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityOperating Income Growing With Multi-Year Revenue GrowthHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hebei Sinopack Electronic Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityOperating Income Growing With Multi-Year Revenue Growth
Beam Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC